Loading
DFP-14927 is an experimental PEGylated polymer conjugate of the nucleoside analogue DFP-10917 from Delta-Fly Pharma, in phase 1 trials for advanced solid tumours.
DFP-14927 is a PEGylated polymer conjugate of the nucleoside analogue DFP-10917 from Delta-Fly Pharma. A large four-arm PEGylated form of DFP-10917 designed for once-weekly dosing. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT03943004 in advanced solid tumours, registry status RECRUITING. Whether it works in people has not been established unless a trial below reports it.
A large four-arm PEGylated form of DFP-10917 designed for once-weekly dosing.
1.DFP-14927 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DFP-14927" OR ABSTRACT:"DFP-14927") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DFP-14927, not a curated reading list.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/